Supernus Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>SP</div>
SUPN -- USA Stock  

USD 22.48  0.52  2.37%

Whilst many millenniums are getting more into healthcare space, it makes sense to outline Supernus Pharmaceuticals. We will check why this entity may not get much respect from institutional investors given the current market uncertainty. Is the stock current valuation justified? We will cover Supernus Pharmaceuticals valuation to give you a better outlook on taking a position in the stock.
Published over a month ago
View all stories for Supernus Pharmaceuticals | View All Stories
Is Supernus Pharmaceuticals outlook positive for September 2020?
This firm currently holds 383.49 M in liabilities with Debt to Equity (D/E) ratio of 0.63, which is about average as compared to similar companies. The company has a current ratio of 3.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Supernus Pharmaceuticals has performance score of 1 on a scale of 0 to 100. The entity has a beta of 0.5723, which indicates possible diversification benefits within a given portfolio. Let's try to break down what Supernus's beta means in this case. As returns on the market increase, Supernus Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Supernus Pharmaceuticals will be expected to be smaller as well. Although it is extremely important to respect Supernus Pharmaceuticals current price movements, it is better to be realistic regarding the information on equity historical returns. The philosophy towards measuring future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By inspecting Supernus Pharmaceuticals technical indicators, you can presently evaluate if the expected return of 0.0344% will be sustainable into the future. Supernus Pharmaceuticals right now has a risk of 2.26%. Please validate Supernus Pharmaceuticals potential upside, as well as the relationship between the accumulation distribution and price action indicator to decide if Supernus Pharmaceuticals will be following its existing price patterns.
We determine the current worth of Supernus Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Supernus Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Supernus Pharmaceuticals's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Supernus Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Supernus Pharmaceuticals. We calculate exposure to Supernus Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Supernus Pharmaceuticals's related companies.

Supernus Pharmaceuticals Investment Alerts

Supernus investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Supernus Pharmaceuticals performance across your portfolios.Please check all investment alerts for Supernus

Supernus Pharmaceuticals Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Supernus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Supernus Pharmaceuticals competition to find correlations between indicators driving the intrinsic value of Supernus.

How Supernus utilizes its cash?

To perform a cash flow analysis of Supernus Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Supernus Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Supernus Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Supernus Pharmaceuticals Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at 154.43 Million

Bona fide gift to Gregory Patrick of 1120 shares of Supernus Pharmaceuticals subject to Section 16

Legal trades by Supernus Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Supernus insider trading alert for gift of common stock by Gregory Patrick, Sr.VP Chief Financial Officer, on 28th of August 2020. This event was filed by Supernus Pharmaceuticals with SEC on 2020-08-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Supernus Pharmaceuticals reported the previous year's revenue of 402.26 M. Net Income was 116.23 M with profit before overhead, payroll, taxes, and interest of 376.1 M.

Margins Breakdown

Supernus profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Supernus Pharmaceuticals itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Supernus Pharmaceuticals profit margins.
Profit Margin
Operating Margin
Operating Margin31.37
EBITDA Margin31.67
Gross Margin90.2
Profit Margin25.2

Supernus Pharmaceuticals Net Income Per Employee is decreasing over the last 8 years. The previous year's value of Supernus Pharmaceuticals Net Income Per Employee was 262,891. Further, Supernus Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years.

Will Supernus Pharmaceuticals continue to go insane?

Latest potential upside is at 4.35. Supernus Pharmaceuticals exhibits very low volatility with skewness of 0.12 and kurtosis of 0.71. However, we advise investors to further study Supernus Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Supernus Pharmaceuticals

Whereas some other firms in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Supernus Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Supernus as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Supernus Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Supernus Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to